Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Perceived Autonomy in Performing Intravenous Injections for Patients With Severe or Moderate Hemophilia A Receiving Emicizumab (APHARIPE)

perjantai 13. marraskuuta 2026 päivittänyt: University Hospital, Caen

Perceived Autonomy of Patients (or Family Caregivers) With Severe or Moderate Hemophilia A for Performing Intravenous Injections Under Emicizumab Prophylaxis

Hemophilia A is a rare inherited bleeding disorder caused by a deficiency in clotting factor VIII (severe if <1%, moderate if 1% to 5%). Until the introduction of emicizumab (Hemlibra®), treatment relied exclusively on frequent intravenous (IV) infusions of clotting factor concentrates (FVIII or bypassing agents), allowing patients or their family caregivers to maintain technical skills and autonomy through regular practice.

Since 2018 (and 2023 for moderate hemophilia A), subcutaneous prophylactic treatment with emicizumab has drastically reduced bleeding episodes and, consequently, the frequency of IV infusions. However, IV injections remain necessary to treat acute breakthrough bleeds. The investigators hypothesize that previously autonomous patients or family caregivers may experience a gradual loss of skill and self-efficacy in performing IV injections while on emicizumab prophylaxis.

The APHARIPE study is a multicenter, non-interventional, exploratory study based on questionnaires administered to 450 previously autonomous patients with severe or moderate hemophilia A (or their family caregivers) receiving emicizumab, as well as their healthcare providers. Over an 18-month inclusion period, this study aims to assess perceived autonomy in performing IV injections, identify potential perception gaps between patients/caregivers and healthcare providers, evaluate the impact on acute bleed management and home emergency treatment storage, and guide future therapeutic education practices.

Tutkimuksen yleiskatsaus

Tila

Ei vielä rekrytointia

Ehdot

Yksityiskohtainen kuvaus

Hemophilia is a rare constitutional bleeding disorder. Severe hemophilia A corresponds to a severe factor VIII (FVIII) deficiency (<1%), and moderate hemophilia A to an FVIII level between 1% and 5%. Both forms manifest as spontaneous or post-traumatic/surgical intra-articular bleeds (hemarthroses) or muscle hematomas, which can jeopardize functional prognosis if recurrent.

Until April 2018, the treatment of severe and moderate hemophilia A was exclusively substitutive, relying on intravenous (IV) injections of clotting factor concentrates (FVIII, or bypassing agents such as rFVIIa or aPCC for patients with anti-FVIII inhibitors). Used both prophylactically (2 to 3 IV infusions per week) and on-demand for acute bleeds, this regimen enabled most patients-or family caregivers for younger children-to acquire and maintain autonomy in performing IV injections through frequent practice.

Since April 2018 for patients with inhibitors, March 2020 for severe hemophilia A without inhibitors, and January 2023 for moderate hemophilia A, subcutaneous prophylaxis with the monoclonal antibody emicizumab (Hemlibra®) has been available. While emicizumab converts the bleeding phenotype to that of mild hemophilia, it is strictly prophylactic; IV clotting factor infusions remain required in the event of breakthrough bleeding. Because bleeding events become very rare under emicizumab, the frequency of IV injections drops sharply.

The investigators hypothesize that patients (or family caregivers) who were previously autonomous in performing IV clotting factor infusions progressively lose technical competence and/or self-efficacy during emicizumab prophylaxis. APHARIPE is a multicenter, exploratory, non-interventional questionnaire-based study designed to evaluate patients' and caregivers' perceived loss of autonomy. Healthcare providers caring for this population will also be surveyed to assess potential perception gaps regarding the impact of this loss of autonomy on overall patient management.

The study aims to include 450 patients (or family caregivers) with severe or moderate hemophilia A treated with emicizumab who were previously autonomous for IV injections, over an 18-month recruitment period. Findings will help identify specific difficulties, question the relevance of ongoing IV injection training, assess the impact on acute bleed management and the need to keep emergency treatments at home, and ultimately optimize patient care pathways and therapeutic education practices

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Arvioitu)

450

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

  • Nimi: Nicolas GUERIN, Registered Nurse
  • Puhelinnumero: + 33 2 31 06 52 10
  • Sähköposti: guerin-n@chu-caen.fr

Opiskelupaikat

      • Pointe-à-Pitre, Guadeloupe, 97110
        • Centre Hospitalier Universitaire de Pointe à Pitre - Hôpital Ricou
        • Ottaa yhteyttä:
      • Angers, Ranska, 49933
        • Centre Hospitalier Universitaire d'Angers
        • Ottaa yhteyttä:
      • Bordeaux, Ranska, 33076
        • Centre Hospitalier Universitaire de Bordeaux - Hôpital Pellegrin
        • Ottaa yhteyttä:
      • Bron, Ranska, 69677
        • Hospices Civiles de Lyon - Hôpital Louis Pradel
        • Ottaa yhteyttä:
      • Caen, Ranska, 14000
        • Centre Hospitalier Universitaire de Caen
        • Ottaa yhteyttä:
          • Nicolas GUERIN, Registered Nurse
          • Puhelinnumero: + 33 2 31 06 52 10
          • Sähköposti: guerin-n@chu-caen.fr
      • Chambéry, Ranska, 73011
      • Clermont-Ferrand, Ranska, 63000
        • Centre Hospitalier Universitaire de Clermont Ferrand
        • Ottaa yhteyttä:
      • Dijon, Ranska, 21079
        • Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand
        • Ottaa yhteyttä:
      • Grenoble, Ranska
        • Centre Hospitalier Universitaire de Grenoble
        • Ottaa yhteyttä:
      • Le Kremlin-Bicêtre, Ranska, 94275
        • AP-HP - Hôpital Bicêtre
        • Ottaa yhteyttä:
      • Le Mans, Ranska
        • Centre Hospitalier du Mans
        • Ottaa yhteyttä:
          • Johann ROSE, Medical Doctor
          • Puhelinnumero: +33 2 44 71 07 50
          • Sähköposti: jrose@ch-lemans.fr
      • Lille, Ranska, 59037
        • Centre Hospitalier Régional Universitaire principal de la métropole lilloise
        • Ottaa yhteyttä:
      • Marseille, Ranska, 13385
        • AP-HM - Hôpitaux Universitaires de Marseille Timone
        • Ottaa yhteyttä:
      • Montpellier, Ranska, 34295
        • Centre Hospitalier Universitaire de Montpellier
        • Ottaa yhteyttä:
      • Nantes, Ranska, 44093
        • Centre Hospitalier Universitaire Hôtel-Dieu
        • Ottaa yhteyttä:
      • Paris, Ranska, 75679
        • AP-HP - Hôpital Cochin
        • Ottaa yhteyttä:
      • Poitiers, Ranska, 86021
        • Centre Hospitalier Universitaire de Poitiers - Hôpital Jean Bernard
        • Ottaa yhteyttä:
      • Pringy, Ranska, 74374
        • Centre Hospitalier Annecy Gennevois
        • Ottaa yhteyttä:
      • Rennes, Ranska
        • Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou
        • Ottaa yhteyttä:
      • Saint-Denis, Ranska, 97400
        • Centre Hospitalier Universitaire de la Réunion
        • Ottaa yhteyttä:
      • Saint-Etienne, Ranska, 45055
        • Centre Hospitalier Universitaire de Saint Etienne - Hôpital Nord
        • Ottaa yhteyttä:
      • Strasbourg, Ranska, 67200
        • Centre Hospitalier Universitaire de Strasbourg - Hôpital de Hautepierre
        • Ottaa yhteyttä:
      • Toulouse, Ranska, 31059
        • Centre Hospitalier Universitaire de Toulouse - Hôpital Purpan
        • Ottaa yhteyttä:
      • Tours, Ranska, 37044
        • Centre Hospitalier Régional Universitaire de Tours - Hôpital Trousseau
        • Ottaa yhteyttä:
      • Vandœuvre-lès-Nancy, Ranska, 54500
        • Centre Hospitalier Régional Universitaire de Nancy - Hôpital Brabois
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Lapsi
  • Aikuinen
  • Vanhempi Aikuinen

Hyväksyy terveitä vapaaehtoisia

Joo

Sukupuolet, jotka voivat opiskella

Kaikki

Näytteenottomenetelmä

Ei-todennäköisyysnäyte

Tutkimusväestö

The study population consists of adult and minor patients with severe (FVIII <1%) or moderate (FVIII 1%-5%) hemophilia A receiving prophylactic treatment with emicizumab for more than 1 year-or parent caregivers (excluding healthcare professionals) for non-autonomous minor patients-who were previously autonomous in performing intravenous clotting factor injections prior to emicizumab initiation. Healthcare professionals (physicians and nurses) involved in the care of these patients will also be enrolled. Participants will be recruited during routine clinical follow-up visits across participating French hemophilia treatment centers

Kuvaus

Inclusion Criteria:

For autonomous adult patients (patient enrolled in the study):

  • Adult patient (>= 18 years old) with severe or moderate hemophilia A
  • Receiving prophylactic treatment with emicizumab for more than 1 year
  • Patient previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
  • Patient non-opposition obtained

For autonomous pediatric/minor patients (patient enrolled in the study):

  • Minor patient (< 18 years old) with severe or moderate hemophilia A
  • Receiving prophylactic treatment with emicizumab for more than 1 year
  • Patient previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
  • Patient non-opposition obtained
  • Non-opposition obtained from parents or legal guardians

For non-autonomous pediatric/minor patients (family caregiver enrolled in the study):

  • Parent caregiver of a child with severe or moderate hemophilia A receiving prophylactic treatment with emicizumab for more than 1 year
  • Parent previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
  • Parent caregiver non-opposition obtained

For healthcare providers:

  • Physician, nurse, or healthcare professional involved in the care of patients with severe or moderate hemophilia A at a participating center
  • Healthcare provider non-opposition obtained

Exclusion Criteria:

For autonomous adult patients:

- Patient not autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation

For autonomous pediatric/minor patients:

- Patient not autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation

For non-autonomous pediatric/minor patients:

- Parent caregiver who is a healthcare professional

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Havaintomallit: OTHER
  • Aikanäkymät: PROSPECTIVE

Kohortit ja interventiot

Ryhmä/Kohortti
Patients or Family Caregivers

Patients with severe or moderate hemophilia A (or family caregivers for pediatric) receiving emicizumab prophylaxis who were previously autonomous in performing intravenous clotting factor injections. Participants will complete a structured questionnaire assessing their perceived autonomy and self-efficacy

Healthcare Providers

Healthcare professionals (physicians, nurses) caring for patients with hemophilia A at participating centers. Participants will complete a specific questionnaire evaluating their perception of patients' potential loss of autonomy for intravenous injections and its impact on clinical management

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Proportion of Patients or Family Caregivers Reporting a Perceived Loss of Autonomy for Performing Intravenous Clotting Factor Injections
Aikaikkuna: At baseline (single questionnaire completion)

Assessed using Question 9 of the study-specific patient/caregiver questionnaire (4-point Likert scale: "not at all autonomous", "slightly autonomous", "moderately autonomous", "completely autonomous"). Responses of "not at all autonomous", "slightly autonomous", or "moderately autonomous" will be classified as a perceived loss of autonomy. Expressed as absolute frequency and percentage of respondents

At baseline (single questionnaire completion)

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Frequency of Clotting Factor Concentrate Use Under Emicizumab Prophylaxis
Aikaikkuna: At baseline (single questionnaire completion)

Absolute and relative frequency (percentage) of patients requiring intravenous clotting factor concentrates (FVIII or bypassing agents) while receiving emicizumab prophylaxis, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients Keeping Clotting Factor Concentrates at Home
Aikaikkuna: At baseline (single questionnaire completion)

Percentage of patients who report having clotting factor concentrates (FVIII or bypassing agents) stored at home, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients or Caregivers Reporting Anticipated Difficulties With Performing a Future Intravenous Injection
Aikaikkuna: At baseline (single questionnaire completion)

Percentage of patients or family caregivers who report experiencing or anticipating difficulties in performing a subsequent intravenous clotting factor injection, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Types of Difficulties Encountered During Intravenous Clotting Factor Injections
Aikaikkuna: At baseline (single questionnaire completion)

Categorization and percentage distribution of specific technical or psychological difficulties reported by patients or family caregivers when performing intravenous injections, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients or Caregivers Expressing a Need for Home Nursing Assistance
Aikaikkuna: At baseline (single questionnaire completion)

Percentage of patients or family caregivers reporting the need for a community nurse (IDE) to perform repeated intravenous clotting factor injections, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients Expressing a Need for a Therapeutic Patient Education Program
Aikaikkuna: At baseline (single questionnaire completion)

Percentage of patients reporting the need for therapeutic education sessions to maintain their autonomy in performing intravenous clotting factor injections, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients or Caregivers Expressing a Need for Initial Intravenous Injection Training
Aikaikkuna: At baseline (single questionnaire completion)

Percentage of patients or family caregivers reporting the need for initial training to learn how to perform intravenous clotting factor injections, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Frequency and Quantity of Unused Expired Clotting Factor Concentrates at Home
Aikaikkuna: At baseline (single questionnaire completion)

Absolute and relative frequency (percentage) of patients having unused expired FVIII concentrates or bypassing agents at home, along with the total number of expired doses reported via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients or Caregivers Reporting an Impact of Perceived Loss of Autonomy on Bleeding Event Management
Aikaikkuna: At baseline (single questionnaire completion)

Absolute and relative frequency (percentage) of patients or family caregivers reporting that their perceived loss of autonomy negatively affected the management of an acute bleeding episode, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Healthcare Providers Supporting the Maintenance of Patient or Caregiver Autonomy for Intravenous Injections
Aikaikkuna: At baseline (single questionnaire completion)

Percentage of healthcare professionals who consider it necessary to maintain patients' or family caregivers' autonomy for intravenous administration of clotting factor concentrates, assessed via the healthcare provider questionnaire

At baseline (single questionnaire completion)
Proportion of Healthcare Providers Supporting the Maintenance of Clotting Factor Concentrates at Home
Aikaikkuna: At baseline (single questionnaire completion)

Percentage of healthcare professionals who consider it necessary to keep emergency clotting factor concentrates at patients' homes, assessed via the healthcare provider questionnaire

At baseline (single questionnaire completion)
Proportion of Healthcare Providers Perceiving a Delay in Bleeding Management Due to Reduced Patient Autonomy
Aikaikkuna: At baseline (single questionnaire completion)

Percentage of healthcare professionals who consider that a decreased sense of autonomy for performing intravenous injections delays the management of acute bleeding episodes, assessed via the healthcare provider questionnaire

At baseline (single questionnaire completion)

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Päätutkija: Nicolas GUERIN, Registered Nurse, Centre Hospitalier Universitaire de Caen - Centre de Ressources et de Compétences Maladies Hémorragiques Rares

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Perjantai 15. tammikuuta 2027

Ensisijainen valmistuminen (Arvioitu)

Perjantai 30. kesäkuuta 2028

Opintojen valmistuminen (Arvioitu)

Perjantai 30. kesäkuuta 2028

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 13. marraskuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 13. marraskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Keskiviikko 18. marraskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Keskiviikko 18. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Perjantai 13. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa